March 24th 2023
Jing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.
March 14th 2023
FDA Grants Priority Review to Avasopasem for Treatment-Related Oral MucositisFebruary 15th 2023
Data from the phase 3 ROMAN trial and the phase 2b GT-201 trial support the new drug application for avasopasem in radiotherapy-induced severe oral mucositis for those with head and neck cancer.
NCCN Guidelines Update Includes Injection for Cisplatin Ototoxicity in AYAsFebruary 14th 2023
A medical oncologist and research audiologist from St. Jude Children’s Research Hospital discuss how sodium thiosulfate injection may improve quality of life by preventing cisplatin-associated ototoxicities in pediatric patients with localized non-metastatic tumors, although more research is needed.
FDA Receives New Drug Application for Avasopasem to Treat Radiotherapy-Induced Severe Oral Mucositis in Head and Neck CancerDecember 15th 2022
The new drug application for avasopasem for radiotherapy-induced severe oral mucositis in patients with head and neck cancer is supported by findings from the phase 3 ROMAN trial and phase 2b GT-201 trial.
Trilaciclib Prior to Sacituzumab Govitecan-hziy Appeared to Reduce AEs in Advanced TNBCNovember 3rd 2022
Initial findings from a phase 2 trial showed trilaciclib given before sacituzumab govitecan-hziy lessened the severity of adverse effects in patients with unresectable locally advanced or metastatic triple-negative breast cancer.
FDA Approves Sodium Thiosulfate to Decrease Cisplatin-Associated Ototoxicity in Pediatric Localized, Non-Metastatic Solid MalignanciesSeptember 21st 2022
Sodium thiosulfate, which appears to be effective in decreasing the risk for hearing loss related to treatment with cisplatin, received FDA approval in pediatric patients with localized, non-metastatic solid tumors.
FDA Approves Eflapegrastim Injection to Decrease Febrile Neutropenia–Related Infection in Non–Myeloid MalignanciesSeptember 12th 2022
Based on evidence from the phase 3 ADVANCE and RECOVER trials, the FDA has approved eflapegrastim-xnst injection to decrease the incidence of infection related to febrile neutropenia for patients with non-myeloid malignancies who are receiving treatment with myelosuppressive anti-cancer agents known to be associated with clinically significant neutropenia.
FDA Greenlights Label Update for Use of Steroids Following Axi-Cel for Management of CRSJanuary 31st 2022
A label update for the CAR T-cell therapy product axicabtagene ciloleucel has been approved by the FDA to allow for use of prophylactic corticosteroid to manage cytokine release syndrome.
Association Found Between Occurrence of Cutaneous Immune-Related AEs and Response to Immunotherapy and SurvivalJanuary 14th 2022
Investigators reported that the development of cutaneous immune-related adverse effects has a strong association with response in survival among patients with cancer treated with immunotherapy.
FDA Issues Complete Response Letter to Plinabulin Application for Prevention of Chemotherapy-Induced NeutropeniaDecember 2nd 2021
A complete response letter has been issued to BeyondSpring Pharmaceuticals for plinabulin plus granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.
EC-18 Yields Positive Results for Chemoradiation-Induced Oral Mucositis in Head and Neck CancerOctober 21st 2021
A phase 2 trial examining the use of small molecule immunomodulator EC-18 in patients with head and neck cancer experiencing chemoradiation-induced oral mucositis met its primary and secondary end points.
New Insights Into Sickle Cell Disease Point to Novel Treatment ParadigmsJanuary 29th 2018
Using a super computer, a team at Brown University has created a model of sickle cell anemia, devising a method that could help researchers assess and evaluate treatments to combat sickle cell disease.